1/9
Looks like no tags are added yet.
Aspirin
Pharm Class: Salicylate/NSAIDs
Therapeutic class: Anti-inflammatory, Antipyretic, Analgesic, Anti-platelet
Precautions:
-Stop at least 1 week prior to surgery, if possible
-Avoid use in children w/ viral illnesses
-Contraindicated w/ active bleeding
Pharmacokinetics:
-Oral: 5-30 min onset; D: 3-6 hr
-Rectal: 1-2 hr onset; D:6-8 hr
AE: n/v, heartburn, epigastric discomfort, occult blood loss, dizziness, tinnitus, acidosis, salicylism toxicity; Reye's syndrome (in children and adolescents)
Interactions: anticoagulants, increased risk of hypoglycemia with oral hypoglycemic agents
Teach patients to report:
-Buzzing in ears, ringing (ototoxicity)
Ibuprofen
Pharm Class: Propionic acid/NSAID
Therapeutic Class: NSAID, Antipyretic, Analgesic
Indication: relief of s/s of rheumatoid arthritis and
OA; relief of mild-mod pain; dysmenorrhea; fever
Action: inhibits prostaglandin synthesis by
block COX 1 and COX 2 receptor sites
AE: h/a, dizziness, somnolence, fatigue, rash, nausea, dyspepsia, bleeding, constipation, bone marrow suppression, MI, stroke
Interactions:
-decreased effect w/loop diuretics
-decreased effect of beta blockers
-Increase lithium toxicity
-increase risk of bleeding w/ anticoagulants, alcohol, glucocorticoids
celecoxib
Pharm Class: Selective COX 2 Inhibitor/NSAID
Therapeutic Class: 2nd generation NSAID for mild to moderate pain
Indication: Last choice med for chronic pain. Arthritis, dysmenorrhea, ST pain
Action: decreases inflammation, fever, and pain by inhibiting COX 2
AE: MI, CVA, h/a, dizziness, sinusitis, nausea, flatulence, diarrhea, rash, peripheral edema
Administration Guidelines: encourage client to take w/ food
Teach risk of MI and stroke d/t suppression of vasodilation
Contraindications: Allergy to sulfonamides
Interactions:
-decreased effect of ACE inhibitors
-Increased INR w/ warfarin
-Increased toxicity of lithium and fluconazole
acetaminophen (Tylenol)
Pharm Class: Centrally Acting Cox Inhibitor
Therapeutic Class: Antipyretic & Analgesic
Action: Acts directly on the hypothalamus to cause vasodilation and sweating, which will reduce fever; MOA of analgesic is not understood
Indications: mild to moderate pain and fever
Pharmacokinetics:
-Oral: onset varies; D:3-6 hr
-IV: onset is immediate; D:4-6 hr
AE: rash, fever, chest pain, liver toxicity and failure, myelosuppression
Interactions:
-increased risk of bleeding d/t liver toxicity
-increased risk of hepatoxicity w/ cirrhosis, ETOH use, barbiturates, carbamazepine, hydantoins, or rifampin
interferon alfa-2B
Pharm Class: Interferon
Therapeutic Class: Immunostimulant
*Prepared by recombinant DNA technology
Indication: hairy cell leukemia, malignant
melanoma, advanced HIV r/t Kaposi sarcoma, chronic Hep B & C, follicular lymphoma
Action: Inhibits growth of tumor cells and enhances
immune response
AE: dizziness, confusion, rash, dry skin, anorexia, nausea, bone marrow suppression, flulike syndrome (fever, chills, fatigue)
Administration Guidelines: Available for IV, IM, and SQ administration
*Prolonged therapy can lead to serous toxicity:
immunosuppression/myelosuppression, hepatotoxicity, neurotoxicity
Interactions: Increased risk of theophylline toxicity
Nursing considerations:
-Teach pt to report fever, malaise, weakness, vaginal yeast infections, gingivitis, and increased bleeding
-Teach pt to report s/s of neurotoxicity, myelosuppression, hepatotoxicity
-Teach pt to rise slowly
aldesleukin
Pharm Class: Interleukin
Therapeutic Class: Immune stimulant
Indication: metastatic renal cell carcinoma in adults; metastatic melanomas
Action: activates human cellular immunity and inhibits tumor growth through increase in lymphocytes, platelets, and cytokines
AE: mental status changes, dizziness, hypotension, sinus tachycardia, arrhythmias, pruritus, n/v, diarrhea, anorexia, GI bleed, bone marrow suppression, respiratory difficulties, fever, chills, pain
Interactions: avoid other cardio or neurotoxic meds-mat exacerbate adverse effects
filgrastim
Pharm Class: CSF
Therapeutic Class: Immune stimulant
Indication: reduction of incidence of infection and time to neutrophil recovery w/myelosuppressive chemotherapy, leukemia, and bone marrow transplants
Action: increased production of neutrophils in bone marrow
AE: h/a, fatigue, alopecia, rash, n/v, diarrhea, stomatitis, anorexia, bone pain, cough, generalized pain
Administration Guidelines:
-Monitor CBC
-Given IV or SQ
cyclosporine
Pharm Class: T and B cell suppressor
Therapeutic Class: immunosuppressant
Indication: prophylaxis for organ rejection in kidney, liver, and heart transplants; RA; Psoriasis
Action: reversibly inhibits immunocompetent lymphocytes; inhibits T helper cells and T suppressor cells, lymphokine production, and release of IL2 and T cell growth factor
AE: tremor, HTN, gingival hyperplasia, renal dysfunction, diarrhea, hirsutism, acne, bone marrow suppression
*AVOID PREGNANCY until at least 4 months after completion
Interactions: avoid other nephro and hepatotoxic agents
*AVOID GRAPEFRUIT JUICE (increases cyclosporine levels)
pembrolizumab
Pharm Class: Monoclonal Antibody
Therapeutic Class: Immunosuppressant
Indications: treatment of cancers: breast, biliary tract, cervical, cutaneous squamous cell, endometrial, esophageal, gastric, head/neck, liver, Merkel cell, lung, kidney; melanoma, Hodgkin lymphoma
Action: inhibits programmed cell death-1 activity from binding to T cells; allows T cells to be more active
AE: cardiovascular toxicity (MI, myocarditis, pericarditis, arrhythmias), rash (severity rangescan be fatal), endocrine alterations, GI variations, liver impairment, GBS, periph. neuropathy, meningitis, ophthalmic toxicity, pulm. toxicity, edema
Interactions: Severe immune suppression can occur if combined with another immunosuppressant agent
omalizumab
Pharm Class: Immune Modulator
Therapeutic Class: Immunosuppressant
Indication: moderate to severe asthma in adults and pediatric patients >6 y.o. w/positive skin test to a perennial aeroallergen (symptoms inadequately controlled by inhaled corticosteroids)
Action: antibody that binds to IgE receptors on mast cells, basophils, and dendritic cells; decreases IgE mediated inflammation
AE: arthralgia, myalgia, fatigue, dizziness, rash, h/a, URI, injection site reactions, anaphylaxis, hypersensitivities
Administration Guidelines: Not for acute attack
SQ every 2-4 weeks